Inhibition of interleukins 12 and 23 - experience of plaque psoriasis therapy by ustekinumab

Abstract

Ustekinumab is a fully human monoclonal antibody that binds to the p40 protein which is a subunit of IL-12 and IL-23rd According to data from clinical trials and clinical practice experience is a very effective treatment for moderate to severe plaque psoriasis with a good safety profile and excellent compliance.

Keywords

• Ustekinumab
• plaque psoriasis therapy